New York, New York--(Newsfile Corp. - November 12, 2026) - Investors who suffered losses on Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL) stock may have claims to recover those losses. Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors that a federal securities class action has been filed on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Anavex securities between November 26, 2025 and August 28, 2026, inclusive (the "Class Period"). Investors who wish to serve as lead plaintiff must move the Court no later than November 30, 2026.

Investors with losses on Anavex securities can contact Faruqi & Faruqi partner Josh Wilson about the Anavex class action to learn about their legal rights and options.

Key facts for Anavex investors

• Class Period: between November 26, 2025 and August 28, 2026

• Lead plaintiff deadline: November 30, 2026

• Disclosures: March 25, 2026 and May 6, 2026

• Stock drops: $1.45 per share, or 34.61%, on March 25, 2026; and $0.22 per share, or 6.59%, on May 7, 2026

What happened?

On March 25, 2026, Anavex issued a press release "announc[ing] that it has withdrawn its application for the marketing authorization of blarcamesine in the EU as an add-on therapy for the treatment of early Alzheimer's disease in adults, which had been under review by the European Medicines Agency (EMA)." The press release said that "[t]he decision to withdraw the application follows feedback from the EMA's Committee for Medicinal Products for Human Use (CHMP) indicating that it would not be in a position to issue a positive opinion for the application at this time." On this news, Anavex's stock price fell $1.45 per share, or 34.61%, to close at $2.74 per share on March 25, 2026.

Then, on May 6, 2026, Anavex reported that a special committee of the Company's board of directors had "terminated the employment of Christopher Missling, PhD as the Company's Chief Executive Officer for Cause," to be "effective immediately, for, among other things, conduct that the Special Committee believed was inconsistent with Company policy." On this news, Anavex's stock price fell $0.22 per share, or 6.59%, to clos at $3.12 per share on May 7, 2026.

"Anavex stock fell 34.61% on March 25, 2026 and 6.59% on May 7, 2026 after the disclosures described in the complaint. The complaint alleges that investors bought Anavex shares during the Class Period without the full picture," said Josh Wilson, a partner at Faruqi & Faruqi, LLP.

What does the complaint allege?

The complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Anavex Life Sciences lacked adequate internal controls; (2) Anavex Life Sciences understated its potential regulatory challenges as a result of misconduct by former CEO Christopher Missling; and (3) as a result, defendants' statements about Anavex Life Science's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Next steps for Anavex investors

Faruqi & Faruqi, LLP is reviewing potential claims on behalf of Anavex investors. Investors with losses can visit www.faruqilaw.com/AVXL or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss the Anavex class action.

If you wish to serve as lead plaintiff, you must move the Court no later than November 30, 2026. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Common questions from Anavex investors

Who is eligible? Investors who purchased or otherwise acquired Anavex securities between November 26, 2025 and August 28, 2026 and lost money may have claims, and can contact the firm to learn whether the Anavex class action affects them.

What is a securities class action? A lawsuit brought on behalf of a group of investors who bought shares at prices alleged to have been inflated by false or misleading statements, in violation of the federal securities laws. The Anavex class action alleges that the Company and its executives made such statements.

Has a lawsuit been filed? Yes. A federal securities class action has been filed against Anavex. Investors who wish to serve as lead plaintiff must move the Court by November 30, 2026. Investors who do nothing remain absent class members, and serving as lead plaintiff is not required to share in any recovery.

Does it cost anything to contact the firm? No. Investors who purchased Anavex securities during the Class Period may contact Faruqi & Faruqi, LLP to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Whistleblower notice

Faruqi & Faruqi, LLP also encourages anyone with information regarding Anavex's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. Individuals with original information may also consider the SEC Whistleblower Program, which can award whistleblowers 10 to 30 percent of the monetary sanctions collected in a successful SEC enforcement action when those sanctions exceed $1 million.

About Faruqi & Faruqi, LLP

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

Related links

• Anavex class action, Faruqi & Faruqi, LLP

• Anavex Life Sciences Corp. SEC filings index, EDGAR

• SEC Whistleblower Program

• Faruqi & Faruqi, LLP

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/323578

Source: Faruqi & Faruqi LLP